Evidence map›Paper›PMID 30090691›Full record

ArticlePeerJ2018

IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with

Aloysius D Loglo, Michael Frimpong, Mabel Sarpong Duah, Fred Sarfo, Francisca N Sarpong, Bernadette Agbavor, Justice K Boakye-Appiah, Kabiru M Abass, Mathias Dongyele, Margaret Frempong and 6 more

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Aloysius D Loglo *Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Michael FrimpongKumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.ORCID 0000-0003-1901-6793
Mabel Sarpong DuahKumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Fred SarfoSchool of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Francisca N SarpongKumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Bernadette AgbavorKumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Justice K Boakye-AppiahInstitute of Infection and Immunity, St George's University of London, London, UK.ORCID 0000-0002-5741-5165
Kabiru M AbassAgogo Presbyterian Hospital, Agogo, Ghana.
Mathias DongyeleTepa Government Hospital, Tepa, Ghana.ORCID 0000-0002-7547-7159
Margaret FrempongSchool of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Sacha PidotDepartment of Microbiology and Immunology, Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-1202-6614
Mark Wansbrough-JonesInstitute of Infection and Immunity, St George's University of London, London, UK.
Timothy P StinearDepartment of Microbiology and Immunology, Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.ORCID 0000-0003-0150-123X
Virginie RoupieService Immunology, Scientific Institute of Public Health, Brussels, Belgium.
Kris HuygenService Immunology, Scientific Institute of Public Health, Brussels, Belgium.
Richard O Phillips *Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.ORCID 0000-0001-8992-0222
Kwame Nkrumah University of Science and Technology · GHInstitut Scientifique de Santé Publique · BESt George's, University of London · GBThe University of Melbourne · AUGhana Education Service · GHPresbyterian University, Ghana · GH

Funding

Medical Research Council MR/J01477X/1
6 · The paper itself

Abstract

backgroundBuruli ulcer is a disease of the skin and soft tissues caused by infection with a slow growing pathogen,

methodsBetween March 2013 and August 2015, heparinized whole blood was obtained from patients confirmed with Buruli ulcer. The blood samples were diluted 1 in 10 in Roswell Park Memorial Institute (RPMI) medium and incubated for 5 days with recombinant mycolactone PKS domains and mycolyltransferase antigen 85A (Ag85A). Blood samples were obtained before and at completion of antibiotic treatment for 8 weeks and again 8 weeks after completion of treatment. Supernatants were assayed for interferon-γ (IFN-γ) and interleukin-5 (IL-5) by enzyme-linked immunosorbent assay. Responses were compared with those of contacts and non-endemic controls.

resultsMore than 80% of patients and contacts from endemic areas produced IFN-γ in response to all the antigens except acyl carrier protein type 3 (ACP3) to which only 47% of active Buruli ulcer cases and 71% of contacts responded. The highest proportion of responders in cases and contacts was to load module ketosynthase domain (Ksalt) (100%) and enoylreductase (100%). Lower IL-5 responses were induced in a smaller proportion of patients ranging from 54% after ketoreductase type B stimulation to only 21% with ketosynthase type C (KS C). Among endemic area contacts, the, highest proportion was 73% responding to KS C and the lowest was 40% responding to acyltransferase with acetate specificity type 2. Contacts of Buruli ulcer patients produced significantly higher IFN-γ and IL-5 responses compared with those of patients to PKS domain antigens and to mycolyltransferase Ag85A of DISCUSSION: The major response to PKS antigen stimulation was IFN-γ and the strongest responses were observed in healthy contacts of patients living in areas endemic for Buruli ulcer. Patients elicited lower responses than healthy contacts, possibly due to the immunosuppressive effect of mycolactone, but the responses were enhanced after antibiotic treatment. A vaccine made up of the most immunogenic PKS domains combined with the mycolyltransferase Ag85A warrants further investigation.

Indexed as

Buruli ulcerImmune responseMycobacterium ulceransPolyketide synthase domains

Identifiers

PMID30090691
PMCPMC6078848
OpenAlexW2887218736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.